Antibodies for Bioanalysis and Drug Monitoring
Develop Robust and Reliable Assays Using Recombinant Anti-Idiotypic Antibodies
We understand the challenges involved in the development of bioanalytical assays to measure levels of large molecule drugs or anti-drug antibodies. You need to design a selective and sensitive assay that works every time, generate translatable and defensible data, and meet your deadlines.
We know you need trustworthy critical antibody reagents to do this.
Without high-quality antibodies you can get stuck developing the method, have to continually requalify new lots, end up feeling insecure about the results, and be frustrated about not making progress.
We offer over 350 antibodies against marketed biologic drugs suitable for pharmacokinetic (PK) and anti-drug-antibody (ADA) assays, to support bioanalytical assays for preclinical research and clinical trials, and therapeutic drug monitoring, for innovator and biosimilar products.
Our team of antibody experts has been making recombinant monoclonal antibodies targeting a wide array of biologics for over 20 years; if a target is not listed in the menu, contact us to discuss a custom antibody project.
Why Choose Bio-Rad
Anti-Idiotypic Antibodies
Discover the ten key reasons our anti-IDs are market leaders
With over 350 products, Bio-Rad offers one of the largest ranges of anti-IDs available on the market.
This downloadable infographic allows you to explore the top reasons to choose from our expansive range of ready-made antibodies, including stringent quality control, specificity testing, and performance guarantee.
Follow These Steps to Successfully Develop Reliable Assays:
-
1. Find the antibodies to your biologic or biosimilar in our list below
-
2. Check the product specifications and data
-
3. Order antibodies and get your project started!
Ready-Made Anti-Biotherapeutic Antibodies
- Abatacept (Orencia)
- Adalimumab (Humira)
- Aflibercept (Eylea)
- Alemtuzumab (Lemtrada)
- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Belatacept (Nulojix)
- Belimumab (Benlysta)
- Benralizumab (Fasenra)
- Bevacizumab (Avastin)
- Brentuximab (Adcetris)
- Burosumab (Crysvita)
- Canakinumab (Ilaris)
- Cemiplimab (Libtayo)
-
Certolizumab pegol
(Cimzia) - Cetuximab (Erbitux)
- Daratumumab (Darzalex)
- Denosumab (Prolia)
- Dupilumab (Dupixent)
- Dulaglutide (Trulicity)
- Durvalumab (Imfinzi)
- Eculizumab (Soliris)
- Elotuzumab (Empliciti)
- Emicizumab (Hemlibra)
- Etanercept (Enbrel)
- Evolocumab (Repatha)
- Golimumab (Simponi)
- Guselkumab (Tremfya)
- Infliximab (Remicade)
- Ipilimumab (Yervoy)
- Isatuximab (Sarclisa)
- Ixekizumab (Taltz)
- Natalizumab (Tysabri)
- Nivolumab (Opdivo)
- Obinutuzumab (Gazyvaro)
- Ocrelizumab (Ocrevus)
- Omalizumab (Xolair)
- Palivizumab (Synagis)
- Panitumumab (Vectibix)
- Pembrolizumab (Keytruda)
- Pertuzumab (Perjeta)
- Ramucirumab (Cyramza)
- Ranibizumab (Lucentis)
- Rituximab (Rituxan)
- Risankizumab (Skyrizi)
- Romosozumab (Evenity)
- Sarilumab (Kevzara)
- Secukinumab (Cosentyx)
- Tocilizumab (Actemra)
- Trastuzumab (Herceptin)
- Tremelimumab (Imjudo)
- Ustekinumab (Stelara)
- Vedolizumab (Entyvio)
Antibodies to ADC Payloads
Develop sensitive assays for the detection of monomethyl auristatin E (MMAE) and for antibody drug conjugates (ADC) incorporating this toxin.
Antibodies to Fc Mutations
Develop highly selective and sensitive PK assays for antibody drugs containing YTE mutations in the Fc region using our range of ready-made antibodies.
What Makes Our Monoclonal Anti-Idiotypic Antibodies So Special?
• Highly specific to drug idiotope or drug-target complex, results in a selective PK assay
• Fully human, ideal as a surrogate positive control or calibrator for an ADA assay
• Sequence defined, well-characterized reagent for secure supply throughout the study
• Recombinant production with stringent quality control for batch-to-batch consistency
• Non-animal-derived antibodies, reduces the use of animals in science
• Imagine how good it would feel to save time and increase your success rates
You have well-characterized antibodies, highly specific to the drug
You can design and optimize a selective and sensitive assay
Your results are translatable and reproducible
Trust our recombinant anti-idiotypic antibodies to help you master the assay, deliver results, increase productivity, and achieve success!
Can’t Find Antibodies to Your Biologic in Our List?
Custom Antibody Development — Useful Reading
Reference
• Harth and Frisch (2021). Recombinant anti-idiotypic antibodies in ligand binding assays for antibody drug development. Methods Mol Biol. 2261:291-306.